Long-Term Effects of Clofibrate (Atromid-S) on Serum Lipids in Man
- 1 May 1969
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 39 (5) , 675-684
- https://doi.org/10.1161/01.cir.39.5.675
Abstract
Clofibrate was administered to 45 patients for varying periods of time up to 4 years with no evidence of chronic toxicity. Clofibrate was more effective in lowering serum triglycerides than serum cholesterol, with more than 75% of all patients with elevated triglycerides having at least a 25% reduction in triglycerides, the absolute reduction in triglycerides being directly correlated with pretreatment values. A reduction in serum cholesterol of 15% or more was obtained in 50% of all patients, those individuals with elevations of triglycerides having the greatest reduction in serum cholesterol as well as being most likely to respond.Keywords
This publication has 19 references indexed in Scilit:
- Effects of ethyl chlorophenoxyisobutyrate on thyroxine distribution, transport and metabolism in manMetabolism, 1968
- Clofibrate effect on catecholamine-induced metabolic changes in humansMetabolism, 1968
- Effect of CPIB ester on plasma free fatty acid levels in manMetabolism, 1966
- EFFECT OF ETHYLCHLORO-PHENOXYISOBUTYRATE ON WEIGHT, PLASMA VOLUME, TOTAL BODY-WATER, AND FREE FATTY ACIDSThe Lancet, 1965
- Studies with ethyl chlorophenoxyisobutyrate (clofibrate)Metabolism, 1965
- The Effect of Chlorophenoxyisobutyric Acid and Ethinyl Estradiol on Cholesterol Turnover*Journal of Clinical Investigation, 1965
- An experimental approach to the problem of disordered lipid metabolismJournal of Atherosclerosis Research, 1963
- EXPERIMENTAL EVALUATION OF AN ORALLY ACTIVE COMBINATION OF ANDROSTERONE WITH ETHYL CHLOROPHENOXYISOBUTYRATEThe Lancet, 1962
- REDUCTION OF SERUM-LIPID AND URIC-ACID LEVELS BY AN ORALLY ACTIVE ANDROSTERONEPublished by Elsevier ,1962
- Individual Comparisons by Ranking MethodsBiometrics Bulletin, 1945